Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: A 5-year follow-up analysis

Anticancer Research

Volumn 23, Issue 2 A, 2003, Pages 969-974

  Repmann, Rüdiger ^a   Goldschmidt, Andreas J W ^b   Richter, Axel ^a  

^a Klinikum St Georg   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Adjuvant therapy; Immunotherapy; Radical nephrectomy; Renal cell carcinoma; Vaccine

Indexed keywords

ADJUVANT AUTOLOGOUS TUMOR CELL LYSATE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADULT; AGE DISTRIBUTION; AGED; CANCER GROWTH; CANCER SURVIVAL; CHI SQUARE TEST; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; RANK SUM TEST; SEX RATIO; SURVIVAL RATE; TUMOR LOCALIZATION; TUMOR VOLUME; VACCINATION;

ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0038538304     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Anton P, Kirchner H, Jonas U and Atzpodien J: Cytokines and tumor vaccination. Cancer Biother Radiopharm 11: 315-318, 1996.
2. Basting R, Corvin S, Handel D, Hinke A and Schmidt D: Adjuvant immunotherapy in renal cell carcinoma-comparison of interferon alpha treatment with untreated control. Anticancer Res 19: 1545-1548, 1999.
3. Dal Bianco M, Arbitani W, Bassi PF, Pescatori E and Pagano F: Prognostic factors in renal cell carcinoma. Eur Urol 15: 73-76, 1988.
4. De Riese W, Goldenberg K, Allhoff E, Stief C, Schlick R, Liedke S and Jonas U: Metastatic renal cell carcinoma (RCC): spontaneous regression, long-term survival and late recurrence. Int Urol Nephrol 23: 13-25, 1991.
5. Dillman RO Nayak SK and Beutel L: Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother 14: 65-69, 1993.
6. Dinney CP, Awad SA, Gajewski JB, Belitsky P, Lannon SG, Mack FG and Millard OH: Analysis of imaging modalities, staging systems, and prognostic indicators for renal cell carcinoma. Urology 39: 122-129, 1992.
7. Figlin RA: Renal cell carcinoma: Management of advanced disease. J Urol 161: 381-387, 1999.
8. Finney R: The value of radiotherapy in the treatment of hypernephroma - a clinical trial. Br J Urol 45: 258-269, 1973.
9. Fischer CC, Wächter WC, Fuentecilla Perez E, Miller J, Weidner W and Dudeck J: Urologische tumoren in Deutschland. Urologe A 36: 143-150, 1997.
10. Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, Santarosa M, Sacco C and Talamini R: Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 77: 2560-2566, 1996.
11. Gansbacher B, Zeier K, Daniels B, Cronin K, Bennerji R and Gilboa E: Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217-1224, 1990.
12. Giuliani L, Gilberti C, Martorana G and Rovida S: Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 143: 468-474, 1990.
13. Guinan PD, Vogelzang NJ, Fremgen AM, Chmiel JS, Sylvester JL, Sener SF and Imperato JP: Renal cell carcinoma: tumor size, stage and survival. J Urol 153: 901-903, 1995.
14. Goldschmidt AJW, Hockertz SW, Repmann R, Richter A, Ulbrich C and Großmann A: Adjuvant therapy of renal cell carcinoma (RCC) with a pure-cell-lysate autologous tumor vaccine (aTm): A 3-year follow-up-analysis. Proc Am Ass Cancer Res 39: 367, 1998.
15. Hermanek P and Schrott KM: Evaluation of the new tumor, nodes and metastases classification of renal carcinoma. J Urol 144: 238-242, 1990.
16. Jeon SH, Chang SG and Kim JI: The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in factors in pT3N0M0 renal cell carcinoma. Anticancer Res 19: 5593-5597, 1999.
17. Kjaer M, Frederiksen PL and Engelholm SA: Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen renal cancer study group. Int J Radiat Oncol Biol Physiol 13: 665-672, 1987.
18. Kriegmair M and Oberneder R: Die tumorzellvakzinierung zur behandlung des nierenzellkarzinoms. Urologe A 34: 204-207, 1995.
19. Levy DA, Slaton JW, Swanson DA and Dinney CP: Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159: 1163-1167, 1998.
20. Makarewicz R, Zarzycka M, Kulinska G and Windorbska W: The value of postoperative radiotherapy in advanced renal cell cancer. Neoplasma 45: 380-383, 1998.
21. McNichols DW, Segura JW and DeWeerd JH: Renal cell carcinoma: long-term survival and late recurrence. J Urol 126: 17-23, 1981.
22. Migliari R, Muscas G, Solinas A, Melis M, Ionta MT, Massidda B and Usai E: Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma? J Chemother 7: 240-245, 1995.
23. Motzer RJ, Bander NH and Nanus DM: Renal cell carcinoma. New Engl J Med 335: 865-875, 1996.
24. Motzer RJ and Russo P: Systemic therapy for renal cell carcinoma. J Urol 163: 408-417, 2000.
25. Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G and Marubini E: Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19: 425-31, 2001.
26. Pomer S, Thiele R, Staehler G, Drehmer L, Lohrke H and Schirrmacher V: Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization. Urologe A 34: 215-220, 1995.
27. Rabinovitch RA, Zelefsky MJ, Gaynor JJ and Fuks Z: Patterns of failure following surgical resection of renal cell carcinoma: implications for adjunct local and systemic therapy. J Clin Oncol 12: 206-212, 1994.
28. Repmann R, Wagner S and Richter A: Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine. Anticancer Res 17: 2879-2882, 1997.
29. Robson CJ, Churchill BM and Anderson W: The results of radical nephrectomy for renal cell carcinoma. J Urol 101: 297-301, 1969.
30. Sandock DS, Seftel AD and Resnick MI: A new protocol for the follow-up of renal cell carcinoma based on pathological stage. J Urol 154: 28-31, 1995.
31. Störkel S, Thoenes W, Jacobi GH and Lippold R: Prognostic parameters in renal cell carcinoma-a new approach. Eur Urol 16: 416-422, 1989.
32. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB and Belldegrun A: Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 163: 1090-1095, 2000.
33. th edition Springer; Berlin/Heidelberg, Germany (1997).
34. Yagoda A, Bassam AR and Petrylak D: Chemotherapy for advanced renal cell carcinoma 1983-1993. Semin Oncol 22: 42-60, 1995.
35. Yasunaga Y, Shin M, Miki T, Okuyama A and Aozasa K: Prognostic factors of renal cell carcinoma: a multivariate analysis. J Surg Oncol 68: 11-18, 1998.